RADX doses first patient in second Phase 1/2a BetaBart cohort
Radiopharm Theranostics (RADX) dosed the first patient in the second cohort of its Phase 1/2a trial of BetaBart (RV-01) in B7-H3 expressing solid tumors.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.